Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01581138 · ClinicalTrials.gov registry record · Phase 2

VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C

A Phase 2 study of Chronic Hepatitis C Virus, sponsored by Vertex Pharmaceuticals Incorporated.

Completed
Registry status
Phase 2
Development phase
64
Enrollment target
18
Study locations

NCT01581138 is a Phase 2 study of Chronic Hepatitis C Virus that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 64 participants, below the 342-participant average among 3 other Chronic Hepatitis C Virus trials with a reported enrollment target (81% lower). The trial reports 18 study locations across 13 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01581138, a Phase 2 study of Chronic Hepatitis C Virus, has completed, sponsored by Vertex Pharmaceuticals Incorporated.

COMPLETED
Registry status
Phase 2
Development phase
64 participants
Enrollment target
18
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy and safety of two all oral regimens in subjects who have chronic hepatitis C and have not received treatment yet.

Conditions Studied

Chronic Hepatitis C Virus

Interventions

  • DRUG ribavirin
  • DRUG telaprevir
  • DRUG VX-222

Study Locations (18)

California

  • - Anaheim
  • - Riverside
  • - San Diego

North Carolina

  • - Asheville
  • - Winston-Salem

Tennessee

  • - Germantown
  • - Nashville

Texas

  • - Austin
  • - San Antonio

Alabama

  • - Birmingham

Colorado

  • - Englewood

Florida

  • - Orlando

Georgia

  • - Marietta

Trial Details

FieldValue
Enrollment Target 64 participants
Start Date 2012-07
Est. Completion 2013-12
Phase Phase 2

Sponsor

Vertex Pharmaceuticals Incorporated

191 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01581138

The ClinicalTrials.gov registry entry for NCT01581138 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 64 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 342-participant average among 3 other Chronic Hepatitis C Virus trials with a reported enrollment target (81% lower). The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Chronic Hepatitis C Virus appearing as the primary indexed condition, and to 3 interventions - of which ribavirin is the first listed.

NCT01581138 reports 18 study locations spanning 13 distinct geographic areas - top geographies include California, North Carolina, Tennessee.

Frequently Asked Questions

What is clinical trial NCT01581138 about?

NCT01581138 is a clinical study titled "VX-222 + Telaprevir + Ribavirin for 12 or 16 Weeks in Treatment-Naive Subjects With Genotype 1a Hepatitis C". The purpose of this study is to evaluate the efficacy and safety of two all oral regimens in subjects who have chronic hepatitis C and have not received treatment yet.

What is the current status of trial NCT01581138?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 64 participants. The study started on 2012-07. Estimated completion is 2013-12.

What conditions does trial NCT01581138 study?

This clinical trial studies the following conditions: Chronic Hepatitis C Virus.

What interventions are being tested in trial NCT01581138?

The interventions under investigation include: ribavirin (DRUG), telaprevir (DRUG), VX-222 (DRUG).

Who is sponsoring clinical trial NCT01581138?

This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01581138 being conducted?

This trial has 18 study locations across Alabama, California, Colorado, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Chronic Hepatitis C Virus

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Chronic Hepatitis C Virus

All registered trials for this condition

Alabama

All trials with a study site in Alabama

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.